Skip to main content
. 2013 Jan 10;18(2):139–157. doi: 10.1089/ars.2011.4491

FIG. 6.

FIG. 6.

Neuroprotective effects of synthetic TP in the MPTP model of Parkinson's disease. (A) Immunohistochemical staining for TH and (B) stereological analysis of total (NISSL) and TH+-neurons in the SNpc in the acute MPTP model on the 7th day after treatment with TP-319 and TP-500. Bars represent mean±SEM. *p<0.05 compared to saline controls, and #p<0.05 compared to MPTP (n=6 mice per group). (C) Striatal levels of DA measured by HPLC analysis in the acute MPTP model on the 7th day. Bars represent mean±SEM. *p<0.05 compared to saline controls, and #p<0.05 compared to MPTP (n=6 mice per group). (D) Immunohistochemical staining for TH and (E) in the substantia nigra in the subacute MPTP model on the 21st day after treatment with TP-319 and TP-500. Bas represent mean±SEM. *p<0.05 compared to saline controls, and #p<0.05 compared to MPTP (n=6 mice per group). (F) Striatal levels of DA measured by HPLC analysis in the subacute MPTP-model on the 21st day. Bars represent mean±SEM. *p<0.05 compared to saline controls, and #p<0.05 compared to MPTP (n=6 mice per group) (scale bar, 200 μm). DA, dopamine; HPLC, high-performance liquid chromatography; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNpc, substantia nigra pars compacta; TH, tyrosine hydroxylase.